Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
54.97
-1.54 (-2.73%)
Aug 20, 2026, 10:48 AM EDT - Market open
Scholar Rock Holding Employees
Scholar Rock Holding had 289 employees as of December 31, 2025. The number of employees increased by 93 or 47.45% compared to the previous year.
Employees
289
Change (1Y)
93
Growth (1Y)
47.45%
Revenue / Employee
n/a
Profits / Employee
-$1,413,810
Market Cap
6.69B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 289 | 93 | 47.45% |
| Dec 31, 2024 | 196 | 46 | 30.67% |
| Dec 31, 2023 | 150 | 36 | 31.58% |
| Dec 31, 2022 | 114 | -31 | -21.38% |
| Dec 31, 2021 | 145 | 26 | 21.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| TG Therapeutics | 399 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
SRRK News
- 3 days ago - Scholar Rock price target raised to $63 from $56 at JPMorgan - TheFly
- 3 days ago - Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status - TheFly
- 5 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 12 days ago - Scholar Rock drops Catalent facility from marketing application for muscle weakness drug - Reuters
- 12 days ago - Scholar Rock to remove Catalent Indiana facility from apitegromab BLA - TheFly
- 12 days ago - Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date - Business Wire
- 13 days ago - Scholar Rock price target raised to $76 from $70 at BMO Capital - TheFly